

N-(3-(5-((2-fluoro-4-iodophenyl)amino)-3,6,8-trimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro pyrido[4,3-d]pyrimidin-1(2H)-yl)phenyl)-3-methyloxetane-3-carboxamide (Compound 18)

2-((1-(3-(5-((2-fluoro-4-iodophenyl)amino)-3,6,8-trimethyl-2,4,7-trioxo-3,4,6,7-tetra hydro pyrido[4,3-d]pyrimidin-1(2H)-yl)phenyl)azetidin-3-yl)oxy)acetamide (Compound 19)

5-((2-fluoro-4-iodophenyl)amino)-1-(3-(3-fluorooxetan-3-yl)phenyl)-3,6,8-trimethyl pyrido[4,3-d]pyrimidine-2,4,7(1H,3H,6H)-trione (Compound 20)

N-(3-(3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl)phenyl)azetidine-3-carboxamide (Compound 21)

20. A pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt of any one of claims 1-19 and one or more pharmaceutically acceptable carriers, diluents, or excipients.
21. Use of a A compound of formula I, Ia, Ib, Ic, its tautomeric form, or its pharmaceutically acceptable salt as claimed in any one of claims 1-19, ~~in the preparation of medicament for use in~~ inhibiting MEK enzymes comprising contacting said MEK enzyme with a composition comprising said compound, in an amount sufficient to inhibit said enzyme, wherein said enzyme is inhibited.
22. The ~~use~~ compound as claimed in claim 21, wherein said MEK enzyme is MEK kinase.
23. The ~~use~~ compound as claimed in claim 21 wherein said contacting occurs within a cell.
24. Use of a A compound of formula I, Ia, Ib, Ic, its tautomeric form, or its pharmaceutically acceptable salt as claimed in any one of claims 1-19, ~~in the preparation of medicament for use in~~ the treatment of a MEK mediated disorder in an individual suffering from said disorder, comprising administering to said individual an effective amount of a composition comprising said compound.

25. The ~~use~~-compound as claimed in claim 24, further comprises administering an additional therapy.
26. The ~~use~~-compound as claimed claim 25, wherein said additional therapy is radiation therapy, chemotherapy or a combination of both.
27. The ~~use~~-compound as claimed claim 24, further comprises administering at least one additional therapeutic agent.
28. The compound ~~use~~-as claimed claim 24, wherein said MEK mediated disorder is selected from the group consisting of inflammatory diseases, infections, autoimmune disorders. Stroke, ischemia, cardiac disorder, neurological disorders, fibrogenetic disorders, proliferative disorders, hyperproliferative disorders, tumors, leukemias, neoplasms, cancers, carcinomas, metabolic diseases and malignant diseases.
29. The compound ~~use~~-as claimed in claim 24, wherein said MEK mediated disorder is a hyperproliferative disease.
30. The compound ~~use~~-as claimed in claim 24, wherein said MEK mediated disorder is cancer, tumors, leukemias, neoplasms, or carcinomas.
31. The compound ~~use~~-as claimed in claim 24, wherein said MEK mediated disorder is an inflammatory disease.
32. The compound ~~use~~-as claimed in claim 24, wherein said individual is a mammal.
33. ~~Use of aA~~ compound of formula I, Ia, Ib, Ic, its tautomeric form, or its pharmaceutically acceptable salt as claimed in any one of claims 1-19, ~~in the preparation of medicament for use in~~ the treatment or prophylaxis of a proliferative disease in an individual in need thereof comprising administering to said individual an effective amount of a composition comprising said compound.
34. The compound ~~use~~-as claimed in claim 33, wherein said proliferative disease is cancer, psoriasis, restenosis, autoimmune disease, or atherosclerosis.
35. ~~Use of aA~~ compound of formula I, Ia, Ib, Ic, its tautomeric form, or its pharmaceutically acceptable salt as claimed in any one of claims 1-19, ~~in the preparation of medicament for use in~~ the treatment or prophylaxis of an

inflammatory disease in an individual in need thereof comprising administering to said individual an effective amount of a composition comprising said compound.

36. The compound use as claimed in claim 35, wherein said inflammatory disease is rheumatoid arthritis or multiple sclerosis.
37. ~~Use of a~~ compound of formula I, Ia, Ib, Ic, its tautomeric form, or its pharmaceutically acceptable salt as claimed in any one of claims 1-19, ~~in the preparation of medicament for~~ use in degrading, inhibiting the growth of or killing cancer cells comprising contacting the cells with an effective amount of a composition to degrade, inhibit the growth of or kill cancer cells, wherein the composition comprises said compound.
38. ~~Use of a~~ compound of formula I, Ia, Ib, Ic, its tautomeric form, or its pharmaceutically acceptable salt as claimed in any one of claims 1-19, ~~in the preparation of medicament offor~~ use in inhibiting tumor size increase, reducing the size of a tumor, reducing tumor proliferation or preventing tumor proliferation in an individual thereof comprising administering to said individual an effective amount of a composition to inhibit tumor size increase, reduce the size of a tumor, reduce tumor proliferation or prevent tumor proliferation, wherein the composition comprises said compound.